Purple Biotech Q2 FY26 net income swings to USD 400,000; operating loss widens to USD 1.3 million

Reuters2026/08/07 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Purple Biotech posted IFRS net income of USD 0.4 million for Q2 2026, swinging from a net loss of USD 1.1 million a year earlier.
IFRS operating loss widened to USD 1.3 million from USD 1.2 million, with R&D spending rising to USD 0.7 million from USD 0.6 million.
IFRS finance income, net climbed to USD 1.7 million from USD 0.1 million on a higher non-cash gain from warrant revaluation.
Cash and cash equivalents and short-term deposits totaled USD 6.1 million at June 30, 2026, seen funding operations through mid-2027.
IM1240 tri-specific antibody is aimed at entering clinical studies in 2027; management said it is pursuing a strategic collaboration and financing alternatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070700PRIMZONEFULLFEED9805874) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Purple Biotech Q2 FY26 net income swings to USD 400,000; operating loss widens to USD 1.3 million

You may also like

Crypto prices